Subscribe To

Price Alert Latest News Economic Calendar News

CLLS / Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will host a live webcast to review the Company's clinical data on the AMELI-01 study (evaluating UCART123) presented at the ASH Annual Meeting, and provide a Company update, on December 13, 2022. Read More

Demo Live Account See Partner Details

Content Topics

Cellectis

Host

Live

Webcast

And

Provide

Company

Update

Webcast and

December

Stock

CLLS

Posted: Dec 1 2022, 16:40

Author Name: GlobeNewsWire

CLLS News

By Seeking Alpha
November 3, 2023

Cellectis: End Of 2023 Data Readouts To Boost CAR-T Prospects

Preliminary data from two early-stage studies are going to be shown at the ASH 2023 conference, showcasing its cell therapy candidates for non-Hodgkin

By GlobeNewsWire
November 1, 2023

Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology compa

By GlobeNewsWire
September 27, 2023

Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology com

By Seeking Alpha
August 4, 2023

Cellectis SA (CLLS) Q2 2023 Earnings Call Transcript

Cellectis SA (NASDAQ:CLLS ) Q2 2023 Earnings Conference Call August 5, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andr

By Pulse2
February 5, 2023

CLLS Stock: 23.01% Drop Explaination

The stock price of Cellectis SA (NASDAQ: CLLS) fell by 23.01% in the most recent trading session. This is why.

By GlobeNewsWire
December 1, 2022

Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology co

By GlobeNewsWire
September 1, 2022

Cellectis Announces Participation in Four Upcoming Investor Conferences in September

NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology c

By The Motley Fool
May 20, 2022

Why Cellectis' Shares Rose 22.7% This Week

The company bucked the recent downward trend for biotech companies.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.